Abstract

ObjectivesThe current research explores the anticancer effects of pH sensitive CVC-ZnO QDs (Carvacrol-loaded Zinc Oxide Quantum Dots) on DMBA induced mammary carcinoma in rats. MethodsFemale SD rats were used, and mammary cancer was induced by chemical carcinogen via subcutaneous injection near the mammary gland. Different concentrations of CVC-ZnO QDs were orally supplemented to evaluate the optimum dose. We assessed the growth rate, body weight changes, tumor volume, tumor incidence and tumor burden in both the inducer and treatment groups. We also evaluated the biochemical parameters (antioxidant status, lipid peroxidation, detoxification enzymes, and lipid profile) and histopathological changes in the kidney and mammary tissues. ResultsOur findings indicate that CVC-ZnO QDs treated rats significantly decreased the tumor weight, incidence, burden, lipid peroxidation levels, phase I detoxification enzyme activities and increased the body weight, phase II detoxification enzyme activities, and antioxidant status compared to the DMBA alone treated rats. CVC-ZnO QDs treatment also altered the lipid profile of plasma and mammary tissue. Furthermore, histopathological results confirmed that the CVC-ZnO QDs protect against DMBA-mediated damage to the mammary and kidney. ConclusionThe findings indicate that the CVC-ZnO QDs administered at 4 mg/kg b.w exhibited a significant anticancer effect against DMBA-induced mammary cancer.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.